Acid on ambulatory blood pressure monitoring and evaluation of amlodipine L indapamide sustained release tablets in treatment of essential hypertension.docVIP

 PAGE \* MERGEFORMAT 9 Acid on ambulatory blood pressure monitoring and evaluation of amlodipine L indapamide sustained release tablets in treatment of essential hypertension [Abstract] Objective: To evaluate acid L-amlodipine tablets Indapamide antihypertensive effects in patients with hypertension and target organ protection. Methods: 60 patients with hypertension were daily benzenesulfonamide acid L-amlodipine and indapamide 2.5mg sustained-release tablets 1.5mg combined oral treatment for 8 weeks. medication before and 8 weeks after medication ambulatory blood pressure monitoring, and record the creatinine clearance rate, urinary albumin, ejection fraction , electrolytes, uric acid and other parameters. Results: After 8 weeks of medication in patients with systolic blood pressure, diastolic blood pressure decreased significantly compared with before treatment there was significant difference (P lt;0.01); blood pressure variability and blood pressure load, significantly decreased after treatment, medication trough to peak ratios in blood pressure was significantly higher than before treatment; compared with before treatment, after 8 weeks of medication endogenous creatinine clearance rate, left ventricular ejection fraction increased significantly decreased urinary albumin, no severe electrolyte and metabolic disorders. Conclusion : acid L-amlodipine indapamide sustained release tablets in hypertensive patients with stable blood pressure and a clear protective effect of target organs. [Keywords: acid Levamlodipine; indapamide sustained release tablets; hypertension Hypertension is a common disease, but also cardiovascular and cerebrovascular risk factors the most important. As socio-economic development and changing lifestyles, the incidence of hypertension in China was a consistent growth trend. Antihypertensive drugs The choice to become the main problem facing doctors. Levamlodipine is a new generation of long-acting dihydropyridine calcium channel